ClinicalTrials.gg
CompletedNCT02837198Updated Aug 21, 2018

Study of FYU-981 in Hyperuricemia (Effect on Two Hyperuricemic Types)

A Phase 2 interventional study of FYU-981 and Topiroxostat in Hyperuricemia, sponsored by Fuji Yakuhin Co., Ltd.. Completed at 1 site in Japan. Open to male participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2018-08-21.

Sponsored by Fuji Yakuhin Co., Ltd. · Phase 2, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
24
Allocation
Non-randomized
Ages
20 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing dotinurad in Hyperuricemia — 3 open to participants now, 3 under way, 2 of them phase 3. dotinurad · Hyperuricemia.

Enrollment
10th of 11
24 · median 201
Started
2016
with 1 other
Phase 2
3 of 11
none open now
Registered
3rd of 11
by date
Lead sponsor
5 of 11
Fuji Yakuhin Co., Ltd.

Among the 11 studies testing dotinurad in Hyperuricemia, this one is the 10th largest by enrollment, is one of 2 that started in 2016, is one of 3 in phase 2, and was the 3rd registered.

Hyperuricemia

240 studies on the registry are indexed under Hyperuricemia; 44 are open to participants now.

Browse Hyperuricemia studies →

Open to participants now

3 of the 11 studies testing dotinurad in Hyperuricemia are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

About dotinurad

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 29 Hyperuricemia studies recruiting now, 8 (28%) set no upper age limit and 13 (45%) stop at 75 or younger; 1 takes children under 18; 6 take healthy volunteers.

This study: 20 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing dotinurad in Hyperuricemia, or all of them as a file.
02

Study summary

To investigate the pharmacodynamics, pharmacokinetics and safety of 7-day-repeated doses of FYU-981 administered orally to male hyperuricemic patients with uric acid-overproduction or uric acid-underexcretion type.

In addition, to investigate the additive effects of the combination of FYU-981 and topiroxostat administered orally to male hyperuricemic patients with uric acid-overproduction type.

03

Conditions studied

  • Hyperuricemia

Browse trials for

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Japanese adult subjects
  • Serum urate level: >= 7.0mg/dL in patients
  • Disease Type: Uric acid-overproduction Type or Uric acid-underexcretion Type

Exclusion criteria

Exclusion Criteria:

  • Gouty arthritis within a year before start of study treatment
  • Mixed type in the classification of hyperuricemia
05

Study design

Phase
Phase 2
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Uric acid-overproduction Type

    FYU-981

    Drug: FYU-981

  • Experimental
    Uric acid- underexcretion Type

    FYU-981

    Drug: FYU-981

  • Experimental
    Uric acid-overproduction Type (combination)

    FYU-981 , Topiroxostat

    Drug: FYU-981 · Drug: Topiroxostat

  • Experimental
    Uric acid- underexcretion Type2

    FYU-981

    Drug: FYU-981

Interventions

  • DrugTopiroxostat

    Also known as: FYX-051

06

What researchers measure

Primary outcomes

  1. Pharmacodynamics (Amount of uric acid excreted in urine)

    Time frame: 1-, 2-, 3-, 4-, 5-, 6-,7-,8- and 9-day

  2. Pharmacodynamics (Renal clearance of uric acid)

    Time frame: 1-, 4- and 7-day

  3. Pharmacodynamics (Fractional uric acid excretion)

    Time frame: 4- and 7-day

  4. Pharmacodynamics (Maximum delta effective uric acid concentration)

    Time frame: 1-, 2-, 3-, 4-, 5-, 6- and 7-day

  5. Pharmacodynamics (Delta area under the serum uric acid concentration-time curve)

    Time frame: 1-, 4- and 7-day

Secondary outcomes

  1. Pharmacokinetics (Cmax: Maximum plasma concentration)

    Time frame: 1-, and 7-day

  2. Pharmacokinetics (Cmin: Minimum plasma concentration)

    Time frame: 1-, 2-, 3-, 4-, 5-, 6- and 7-day

  3. Pharmacokinetics (Tmax: Time to reach the peak plasma concentration)

    Time frame: 1-, and 7-day

  4. Pharmacokinetics (T1/2: Elimination half-life of plasma concentration)

    Time frame: 1-, and 7-day

  5. Pharmacokinetics (AUC: Area under the plasma concentration-time curve)

    Time frame: 1-, and 7-day

  6. Pharmacokinetics (kel: Elimination rate constant)

    Time frame: 1-, and 7-day

  7. Pharmacokinetics (Vd/F: Distribution volume / Fraction of dose absorbed)

    Time frame: 1-, and 7-day

  8. Pharmacokinetics (CLtot/F: Total clearance / Fraction of dose absorbed)

    Time frame: 1-, and 7-day

  9. Pharmacokinetics (MRT: Mean residence time)

    Time frame: 1-, and 7-day

07

Study locations

1 site
  • Tokyo, Japan
08

References and documents

Publications

  • Okui D, Sasaki T, Fushimi M, Ohashi T. The effect for hyperuricemia inpatient of uric acid overproduction type or in combination with topiroxostat on the pharmacokinetics, pharmacodynamics and safety of dotinurad, a selective urate reabsorption inhibitor. Clin Exp Nephrol. 2020 Mar;24(Suppl 1):92-102. doi: 10.1007/s10157-019-01817-3. Epub 2019 Nov 16. PubMed 31734820 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2016, a primary completion of Aug 2017 and a completion of Mar 2018. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 15, 2016
First posted
Jul 19, 2016
Start
Jul 2016
Primary completionActual
Aug 2017
CompletionActual
Mar 2018
Last update
Aug 21, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 21, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02837198
Lead sponsor
Fuji Yakuhin Co., Ltd.
Responsible party
Sponsor
First posted
Jul 19, 2016
Start date
Jul 2016
Primary completion
Aug 2017
Completion
Mar 2018
Last update
Aug 21, 2018

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dotinurad

Start the discussion